Table 1.

Clinical and demographic data of the samples collected from DILI patients, included in the study, classified according to clinical variables

	Cholestasic	Mixed type	Hepatocellular (HepC)	Recovered	Chol. vs. HepC	Chol. vs. Mixed	Mixed vs. HepC
Samples (n)	80	54	34	115	NA	NA	NA
R-score	0.8 ± 0.4 [0.2–2.0]	2.5 ± 0.9 [1.3–4.8]	15 ± 13 [5.0–71.5]	0.9 ± 0.5 [0.2–2.5]	< 0.0001†	< 0.0001†	< 0.0001†
ALT	103 ± 105 [13–675]	133 ± 94 [56–438]	744 ± 645 [125–2341]	28 ± 12 [7–54]	< 0.0001†	0.09†	< 0.0001†
ALP	341 ± 280 [148–1617]	138 ± 83 [53–487]	128 ± 66 [60–413]	87 ± 27 [36–145]	< 0.0001†	< 0.0001†	0.5†
AST	74 ± 62 [11–374]	82 ± 75 [25–460]	482 ± 578 [47–2237]	29 ± 14 [12–139]	< 0.0001†	0.5†	0.0003†
GGT	472 ± 616 [10–3268]	189 ± 207 [27–1068]	249 ± 189 [25–895]	61 ± 60 [8–298]	0.004†	0.0002†	0.2†
Total bilirubin	7 ± 10 [0.2–56.8]	2 ± 5 [0.3–36.1]	8 ± 14 [0.4–47.6]	0.7 ± 0.6 [0.2–4.0]	0.7†	0.0003†	0.02†
Albumin	3.9 ± 0.6 [2.9–4.9]	4.1 ± 0.5 [2.8–5.1]	3.9 ± 0.6 [2.4–4.7]	4.3 ± 0.4 [3.2–5.2]	0.9†	0.01†	0.06†
Tryglycerides	122 ± 127 [0–459]	115 ± 127 [49–748]	34 ± 43 [0–205]	122 ± 72 [12–334]	0.0003†	0.0004†	0.9†
Cholesterol	289 ± 262 [50–1621]	207 ± 44 [80–321]	166 ± 73 [25–297]	198 ± 53 [32–356]	0.0005†	0.01†	0.008†
Glucose	91 ± 16 [54–157]	94 ± 30 [64–232]	99 ± 35 [63–249]	94 ± 21 [61–205]	0.2†	0.5†	0.5†
Creatinine	0.9 ± 0.4 [0.4–2.29]	0.7 ± 0.2 [0.19–1.79]	0.9 ± 0.9 [0.3–5.6]	0.8 ± 0.4 [0.21–3.18]	0.8†	0.005†	0.2†
Age	49 ± 21 [9–90]	46 ± 17 [9–78]	46 ± 18 [15–77]	51 ± 17 [20–79]	0.5†	0.4†	0.9†
BMI	24 ± 3 [18–28]	25 ± 3 [17–35]	25 ± 5 [17–34]	25 ± 3 [19–32]	0.1†	0.2†	0.6†
Sex (male/female)	(46/34)	(24/30)	(16/18)	(47/68)	0.9‡	0.9‡	0.9‡

Values within box brackets represent the range

Chol. cholestatic DILI, Mixed mixed DILI, HepC. hepatocellular DILI, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, GGT gamma-glutamyl transferase

^†Comparison of mean values: t test p value (unequal variances)

^‡Comparison of proportions: N − 1 Chi-squared test p value